KR20260007630A - 생물 활성이 저하된 항체 배리언트 - Google Patents
생물 활성이 저하된 항체 배리언트Info
- Publication number
- KR20260007630A KR20260007630A KR1020257042067A KR20257042067A KR20260007630A KR 20260007630 A KR20260007630 A KR 20260007630A KR 1020257042067 A KR1020257042067 A KR 1020257042067A KR 20257042067 A KR20257042067 A KR 20257042067A KR 20260007630 A KR20260007630 A KR 20260007630A
- Authority
- KR
- South Korea
- Prior art keywords
- nemolizumab
- antibody
- variant
- peptide
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2021-207714 | 2021-12-22 | ||
| JP2021207714 | 2021-12-22 | ||
| KR1020237004346A KR102902883B1 (ko) | 2021-12-22 | 2022-12-21 | 생물 활성이 저하된 항체 배리언트 |
| PCT/JP2022/047035 WO2023120561A1 (ja) | 2021-12-22 | 2022-12-21 | 生物活性が低下した抗体バリアント |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237004346A Division KR102902883B1 (ko) | 2021-12-22 | 2022-12-21 | 생물 활성이 저하된 항체 배리언트 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20260007630A true KR20260007630A (ko) | 2026-01-14 |
Family
ID=86902603
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257042067A Pending KR20260007630A (ko) | 2021-12-22 | 2022-12-21 | 생물 활성이 저하된 항체 배리언트 |
| KR1020237004346A Active KR102902883B1 (ko) | 2021-12-22 | 2022-12-21 | 생물 활성이 저하된 항체 배리언트 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237004346A Active KR102902883B1 (ko) | 2021-12-22 | 2022-12-21 | 생물 활성이 저하된 항체 배리언트 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250163163A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4455163A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7721630B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260007630A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613503A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340249A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023120561A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3284480T3 (fi) | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
| WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
| WO2010064697A1 (ja) | 2008-12-05 | 2010-06-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2418220T (pt) * | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| KR20260090008A (ko) * | 2017-11-01 | 2026-06-16 | 추가이 세이야쿠 가부시키가이샤 | 생물 활성이 저하된 항체 배리언트 및 아이소폼 |
| SG11202009629YA (en) * | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
| WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
-
2022
- 2022-12-21 WO PCT/JP2022/047035 patent/WO2023120561A1/ja not_active Ceased
- 2022-12-21 KR KR1020257042067A patent/KR20260007630A/ko active Pending
- 2022-12-21 CN CN202280089597.4A patent/CN118613503A/zh active Pending
- 2022-12-21 EP EP22911263.6A patent/EP4455163A4/en active Pending
- 2022-12-21 TW TW111149176A patent/TW202340249A/zh unknown
- 2022-12-21 JP JP2023501876A patent/JP7721630B2/ja active Active
- 2022-12-21 US US18/721,311 patent/US20250163163A1/en active Pending
- 2022-12-21 KR KR1020237004346A patent/KR102902883B1/ko active Active
-
2023
- 2023-08-22 JP JP2023134673A patent/JP7812826B2/ja active Active
-
2026
- 2026-01-29 JP JP2026012833A patent/JP2026063423A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007142325A1 (ja) | 2006-06-08 | 2007-12-13 | Chugai Seiyaku Kabushiki Kaisha | 炎症性疾患の予防または治療剤 |
| WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
| WO2010064697A1 (ja) | 2008-12-05 | 2010-06-10 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
Non-Patent Citations (1)
| Title |
|---|
| N Engl J Med 2020; 383:141-150 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023120561A1 (cg-RX-API-DMAC7.html) | 2023-06-29 |
| WO2023120561A1 (ja) | 2023-06-29 |
| KR102902883B1 (ko) | 2025-12-22 |
| US20250163163A1 (en) | 2025-05-22 |
| EP4455163A1 (en) | 2024-10-30 |
| JP7721630B2 (ja) | 2025-08-12 |
| JP2023159309A (ja) | 2023-10-31 |
| TW202340249A (zh) | 2023-10-16 |
| KR20240117039A (ko) | 2024-07-31 |
| CN118613503A (zh) | 2024-09-06 |
| JP2026063423A (ja) | 2026-04-10 |
| JP7812826B2 (ja) | 2026-02-10 |
| EP4455163A4 (en) | 2025-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7716441B2 (ja) | 獣医用抗il-31抗体 | |
| US20260092111A1 (en) | Trem2 antibodies and uses thereof | |
| AU2018241141B2 (en) | Pertuzumab variants and evaluation thereof | |
| EP3819313A1 (en) | Bispecific antibody and use thereof | |
| RS63513B1 (sr) | Anti-transtiretin antitela | |
| RS63906B1 (sr) | Anti-transtiretin antitela | |
| US12110330B2 (en) | Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof | |
| JP2026063423A (ja) | 生物活性が低下した抗体バリアント | |
| TW201636372A (zh) | 抗甲狀腺素運送蛋白抗體 | |
| WO2021216810A1 (en) | Long-acting anti-il31 antibodies for veterinary use | |
| US20260035465A1 (en) | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof | |
| US20260034211A1 (en) | PHARMACEUTICAL COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND rHuPH20 OR VARIANTS OR FRAGMENTS THEREOF | |
| JP7097433B2 (ja) | 宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法 | |
| CN117203233A (zh) | 抗tslp抗体组合物及其用途 | |
| CN121930345A (zh) | 抗-pd-1抗体 | |
| JP2019508380A (ja) | Egfrに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性 | |
| HK40108969A (en) | Antibody variant with reduced biological activity | |
| CN111234021A (zh) | 一种抗ccr5抗体及其在治疗肿瘤中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |